Erythropoietin treatment in the neuropsychiatric porphyrias

Clinica Chimica Acta

Volumn 338, Issue 1-2, 2003, Pages 61-66

  Winkler, Andrea S ^a   Peters, Timothy J ^a   Marsden, Joanne T ^a   Deacon, Allan C ^a   Chandler, Georgina ^a   Macdougall, Iain C ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Anaemia; Erythropoietin; Neuropsychiatric porphyrias

Indexed keywords

AMINOLEVULINIC ACID; C REACTIVE PROTEIN; CREATININE; CYANOCOBALAMIN; FERRITIN; FOLIC ACID; PORPHOBILINOGEN; PORPHYRIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; MALE; PORPHYRIA; PRIORITY JOURNAL; QUALITY OF LIFE; RETICULOCYTE COUNT; THROMBOCYTE COUNT;

EID: 0344154579     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2003.07.015     Document Type: Article

References (22)

1. Winkler A.S., Marsden J., Deacon A., Wilson S., Chandler G., Macdougall I.et al. Serum erythropoietin levels are inappropriately low in the acute neuropsychiatric porphyrias. Clin. Chim. Acta. 317:2002;93-100.
2. Caro J., Brown S., Miller O., Murray T., Erslev A.J. Erythropoietin levels in uremic nephric and anephric patients. J. Lab. Clin. Med. 93:1979;449-458.
3. Baer A.N., Dessypris E.N., Goldwasser E., Krantz S.B. Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br. J. Haematol. 66:1987;559-564.
4. Miller C.B., Jones R.J., Piantadosi S., Abeloff M.D., Spivak J.L. Decreased erythropoietin response in patients with the anemia of cancer. N. Engl. J. Med. 322:1990;1689-1692.
5. Henry D.H., Beall G.N., Benson C.A., Carey J., Cone L.A., Eron L.J.et al. Recombinant human erythropoietin in the treatment of the anaemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. Ann. Intern. Med. 117:1992;739-748.
6. Biaggioni I., Robertson D., Krantz S., Jones M., Haile V. The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann. Intern. Med. 121:1994;118-181.
7. Hoeldtke R.D., Streeten D.H.P. Treatment of orthostatic hypotension with erythropoietin. N. Engl. J. Med. 329:1993;611-615.
8. Winkler A.S., Marsden J., Chaudhuri K.R., Hambley H., Watkins P.J. Erythropoietin depletion and anaemia in diabetes. Diabet. Med. 16:1999;813-819.
9. Winkler A.S., Marsden J., Parton M., Watkins P.J., Chaudhuri K.R. Erythropoietin deficiency and anaemia in multiple system atrophy. Mov. Disord. 16:2001;233-239.
10. Macdougall I.C. Treatment of renal anaemia with recombinant human erythropoietin. Curr. Opin. Nephrol. Hypertens. 1:1992;210-219.
11. Birgegard G., Gudbjörnsson B., Hällgren R., Wide L. Anemia of chronic inflammatory arthritides: treatment with recombinant erythropoietin. Gurland H.J., Moran J., Samtleben W., Scigalla P., Wieczorek L. Erythropoietin in renal and non-renal anemias. Update on basic research and clinical applications. Contributions to nephrology. 1991;282-293 Karger, London.
12. Winkler A.S., Landau S., Watkins P.J., Chaudhuri K.R. Observations on haematological and cardiovascular effects of erythropoietin treatment in multiple system atrophy with sympathetic failure: a case report. Clin. Auton. Res. 2:2002;203-206.
13. Mauzerall J.D., Granick S. The occurrence and determination of 5-aminolaevulinic acid and porphobilinogen in urine. J. Biol. Chem. 219:1956;435-466.
14. Deacon A.C. Performance of screening tests for porphyria. Ann. Clin. Biochem. 25:1988;392-397.
15. Raja K.B., Sandhu K., Laftah A., Maxwell P.H., Ratcliffe P.J., Simpson R.J.et al. Erythropoietin: effects on haem biosynthesis. Clin. Sci. 98:2000;10.
16. Heidenreich S., Rahn K.H., Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int. 39:1989;259-265.
17. Bode-Börger S., Kuhn M., Radermacher J., Frölich J.C. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int. 50:1996;1255-1261.
18. Martin W., Smith J.A., White D.G. The mechanisms by which haemoglobin inhibits the relaxation of rabbit aorta induced by nitrovasodilators, nitric oxide, or bovine retractor penis inhibitory factor. Br. J. Pharmacol. 89:1996;563-571.
19. Jandeleit K., Heintz B., Gross-Heitfeld E., Kindler J., Sieberth H.G., Kirsten R.et al. Increased activity of the autonomic nervous system and increased sensitivity to angiotensin II infusion after therapy with recombinant human erythropoietin (Letter). Nephron. 56:1990;220-221.
20. Raine A.E.G. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implication of erythropoietin therapy. Lancet. 1:1988;97-99.
21. Siren A.L., Fratelli M., Brines M., Goemand C.et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. U. S. A. 98:2001;4044-4049.
22. Horina J.H., Wold P. Epoetin for severe anemia in hepatoerythropoietic porphyria. N. Engl. J. Med. 342:2000;1294-1295.